Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't want to wait not even one more day, will be selling all my shares today.
NOT................
SBFM$$$$$$$$$$$$$$$$$$$$
20 on the breakout board, the climb to the top has been set in motion.
SBFM$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Should be closer to .03 by EOD
Looks like the MM"s are scrambling a bit to catch up
Next leg up.
$$$$$$$$MLFB
He is motivated by money and notoriety, he is getting the work done first to get the biggest bang for his busk.
He will probably reevaluate the company when further milestones have been reached.
Keep in mind he is getting older and will not have the chance to start out any other companies, this may be his last chance at a good retirement and fame.
You spend too much time trying to understand the motivation of others and are very impatient.
SBFM number 27 on the Breakout Board, there has to be some info out there we are not aware of yet.
The fuse has been lit, fasten your seatbelts and keep your hands inside the ride at all times.
Try to break up your sell orders and not all one large sale.
I have only seen morning releases, most before trading
Looks like a dip to load before the move up.
Moving up on the BO board.
Look under hot at the top part of the Ihub page.
The board lists tickers that are likely to have significant price movement.
SBFM just made it onto the breakout board, something is a brewing....
So exciting to be part of this play.
I feel that today is going to be the start of aggressive upward movement after news.
Past releases indicate that today is a great day for great news.....
Be ready to be rewarded
We have to keep in mind that all of the releases so far have been Pr's....
What we are waiting on is news..
People comment on good news or not but think for a second.....
We have not heard that either medications do not work as anticipated nor have they gone back to try again so to speak.
As long as we do not hear words like ineffective or thought it would better, the success is inevitable for those who are willing to give this very complicated process a chance.
People on this board complain that we have yet to hear the news we are waiting for, how can they release news before the testing is completed and putting a timeline on success is challenging at best when you are dealing with a new discovery.
Let it breath people, we have not heard bad news, that is as good as good news.
I guess your money is gone.
Wrong.
600 K plus
I find it amazing the comments people make with no effort to know the truth.
I just posted this morning information that proves advancement on the Adva-27a as well as the generic drug pursuits.
You are wrong.
There have been advancements of the Cancer drug.
Adva-27a - Product Profile - BCIQ
Take a look at the website below, this is very telling and exciting.
Holly $hit,I'm pumped
https://bciq.biocentury.com/products/adva-27a
I feel we are all going to get a Christmas present today or tomorrow. This is an exciting time to be part of SBFM.
As indicated by RBC, good things are on their way soon. They obviously have inside knowledge of what is in the works, they seem to be excited to support SBFM in both Cancer and Covid pursuits.
It is time for a double whammy, I bet they even have preliminary results for mouse testing and cell cultures to destroy the virus.
Adva -27a may have been received from China and testing underway, maybe even better than first indicated.
Wow, what an exciting time .....
If anyone is looking to get out for Christmas money, I'll buy what you have....All of it.
This is the first stock I ever bought.
I've had it for years and have been adding throughout.
Sittin on a good stack
Typing in red adds to the perception of fear, great choice.
Now go find a ticker where your comments might be true.
Feel free to provide facts with your statements, it may lessen you being a joke to all of us.
So an all time high makes this a pos to you?
I'm sure there is great benefit to you to try and kill the momentum, great trading philosophy.
I'll never understand people like you that just feel they need to say something.....great work
I think you are wrong.
Based on past history we are due for news today or tomorrow.
Start the day off by smacking the ask and hold on for the imminent PR.
This should be an introduction into mouse testing and results for cell culture that should be complete any time now.
We are also due for update as soon as China sends the Adva-27a for testing in Montreal.
These are exciting time and will be a great reason to remember something good out of 2020.
$$$$$$$$$$$$$$$$$$SBFM$$$$$$$$$$$$$$$$$$
Looks like we are at .02 premarket
Nice to see you back, hope the celebration is close.
Always up for a good party.
one bite at a time
Update this week would make sense. I know that testing is well underway and the results will have a direct impact on PPS, not like the past few updates.
It is hard to be patient especially with the low PPS but the reward is just out of reach for a bit more time.
Most companies at this stage would be putting out PR's all the time to encourage stock sales. Why is this company not pushing for greater share sales; simple, there is either a NDA or buyout negotiations are well underway.
This ticker is not following a typical path for a reason, remember that the great doctor has already established and sold a pharma company with a market cap of over a billion, he know what he is doing....
Stay the course, life will change for us and the world very soon.
SBFM$$$$$$$$$$$$$$$$$$$$$$
This is the competition
Oral Drug Blocks SARS-CoV-2 Transmission, Georgia State Biomedical Sciences Researchers Find
Oral Drug Blocks SARS-CoV-2 Transmission, Georgia State Biomedical Sciences Researchers Find
DECEMBER 3, 2020
coronavirus sars-cov-2 covid-19
Media Contact
LaTina Emerson
Associate Director of Communications
Institute for Biomedical Sciences
Georgia State University
404-413-1353
lemerson1@gsu.edu
ATLANTA—Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
MK-4482/EIDD-2801 is in advanced phase II/III clinical trials against SARS-CoV-2 infection.
Co-authors of the study include R.M. Cox, J.D. Wolf and R.K. Plemper at Georgia State.
The study was funded by public health service grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases to Georgia State.
To read the study, visit https://www.nature.com/articles/s41564-020-00835-2.
I don't know why.
The batch is for mouse testing.
If you have money, buy more.
It is always nice to have someone question everything that has been dissected to death already.
I'm sure you can get excited about this stock once you catch up to the people that have been here for a long time.
Maybe you and Niceguy should get together and provide a what if outlook on everything.
Just saying, you 2 would make a great couple.
This is good news, always a surprise how far things have gone and what amazing finds we have for both streams.
I would say we are now due for a news update on SBFMPL-4 to confirm findings on in vitro work completed. I'm sure this will have moved forward faster than we had thought and with amazing results.
Time to shine SBFM$$$$$$$$$$$$$$$$$$
Looks like the PPS direction will continue to rise, these updates will come a steady pace moving forward.... Cancer and Covid updates are imminent.
We are now waiting for preliminary testing for Adva-27a and SBFMPL-4.
Its a great time to be a long here, payoffs will be remembered for a long time to come.
Buy now or cry later, who wants to tell their friends about what could have been.
SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF Adva-27a FOR TESTING ON TOPII AMPLIFIED CANCERS
Montreal, Quebec, Canada -- December 8, 2020 -- InvestorsHub NewsWire -- Sunshine Biopharma Inc. (OTC PINK: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has ordered a new batch of Adva-27a from its manufacturer in China. The material will be delivered to the laboratories of Sunshine Biopharma's drug development partner in Montreal (Canada). Sunshine plans to use the material to conduct testing on various types of cancer cells that overproduce Topoisomerase II (TopII). Following these cell culture studies, Sunshine will proceed to performing studies on mice harboring tumors of human origin with TopII amplification. TopII is an essential cell cycle enzyme that is amplified in approximately 4% of all human cancers.
"All cancer types that have amplification of the Topoisomerase II gene are potential new targets for our Adva-27a," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This is an additional application for our Adva-27a beyond the original multidrug resistance indication," he added.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.